Page 66 - Genentech News Today

California scientists race to concoct compounds that rewire the brain without euphoria or hallucinations.

California scientists race to concoct compounds that rewire the brain without euphoria or hallucinations.

California scientists race to concoct compounds that rewire the brain without euphoria or hallucinations.

California scientists race to concoct compounds that rewire the brain without euphoria or hallucinations.

California scientists race to concoct compounds that rewire the brain without euphoria or hallucinations.

California scientists race to concoct compounds that rewire the brain without euphoria or hallucinations.

California scientists race to concoct compounds that rewire the brain without euphoria or hallucinations.

<p>A woman who never developed Alzheimer's despite a strong genetic predisposition may hold the key to stopping the disease in its tracks. Studying the woman's unique complement of genetic mutations, researchers at Washington University School of Medicine in St. Louis have found clues that could help cut the link between the early, asymptomatic stage and the late stage, when cognitive decline sets in.</p>

MAINZ, Germany, December 12, 2023 – BioNTech SE will inaugurate its first African site in Kigali, Rwanda, on Monday, December 18th, 2023. The inauguration takes place on the occasion of the set-up...

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting.